These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20207821)

  • 1. Lymphangiogenesis-independent resolution of experimental edema.
    Ongstad EL; Bouta EM; Roberts JE; Uzarski JS; Gibbs SE; Sabel MS; Cimmino VM; Roberts MA; Goldman J
    Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H46-54. PubMed ID: 20207821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The resolution of lymphedema by interstitial flow in the mouse tail skin.
    Uzarski J; Drelles MB; Gibbs SE; Ongstad EL; Goral JC; McKeown KK; Raehl AM; Roberts MA; Pytowski B; Smith MR; Goldman J
    Am J Physiol Heart Circ Physiol; 2008 Mar; 294(3):H1326-34. PubMed ID: 18203849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
    Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
    J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B.
    Onimaru M; Yonemitsu Y; Fujii T; Tanii M; Nakano T; Nakagawa K; Kohno R; Hasegawa M; Nishikawa S; Sueishi K
    Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1685-96. PubMed ID: 19734356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.
    Goldman J; Rutkowski JM; Shields JD; Pasquier MC; Cui Y; Schmökel HG; Willey S; Hicklin DJ; Pytowski B; Swartz MA
    FASEB J; 2007 Apr; 21(4):1003-12. PubMed ID: 17210781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
    Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
    Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of lymphatic capillary regeneration by interstitial flow in skin.
    Goldman J; Conley KA; Raehl A; Bondy DM; Pytowski B; Swartz MA; Rutkowski JM; Jaroch DB; Ongstad EL
    Am J Physiol Heart Circ Physiol; 2007 May; 292(5):H2176-83. PubMed ID: 17189348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.
    Chung ES; Chauhan SK; Jin Y; Nakao S; Hafezi-Moghadam A; van Rooijen N; Zhang Q; Chen L; Dana R
    Am J Pathol; 2009 Nov; 175(5):1984-92. PubMed ID: 19808642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation.
    Huggenberger R; Ullmann S; Proulx ST; Pytowski B; Alitalo K; Detmar M
    J Exp Med; 2010 Sep; 207(10):2255-69. PubMed ID: 20837699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis.
    Kajiya K; Sawane M; Huggenberger R; Detmar M
    J Invest Dermatol; 2009 May; 129(5):1292-8. PubMed ID: 19005491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
    García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
    J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
    Chen HM; Tsai CH; Hung WC
    Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis.
    Jones D; Xu Z; Zhang H; He Y; Kluger MS; Chen H; Min W
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2553-61. PubMed ID: 20864667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
    Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
    Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
    Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-C/VEGFR-3 axis protects against pressure-overload induced cardiac dysfunction through regulation of lymphangiogenesis.
    Lin QY; Zhang YL; Bai J; Liu JQ; Li HH
    Clin Transl Med; 2021 Mar; 11(3):e374. PubMed ID: 33783987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.